Last updated: 09/30/2025 12:30:08

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing with GSK4347859 in Healthy Participants

GSK study ID
221220
Clinicaltrials.gov ID
NCT06188507
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Other
Other
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3996401 Following Single and Multiple Ascending Doses of GSK4347859 in Healthy Participants
Trial description: This is a first time in human (FTiH) study which means that this is the first time that GSK4347859 is given to humans. The study is designed to investigate the safety, tolerability, and concentration of GSK3996401 (the activated form of GSK4347859) in the blood following single ascending doses (Part 1) and multiple ascending doses (Part 2) of GSK4347859 in healthy participants. Part 1 consists of 2 planned cohorts with up to 4 treatment periods in each and is expected to have up to 8 dose levels. Part 2 will investigate 14 days of repeat dosing in 3 cohorts with 3 dose levels.
Primary purpose:
Treatment
Trial design:
Sequential
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Part 1 - Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Timeframe: Up to Day 15

Part 2 - Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Timeframe: Up to Day 30

Part 1 - Number of Participants with Clinically Significant Changes in Haematology

Timeframe: Up to Day 15

Part 2 - Number of Participants with Clinically Significant Changes in Haematology

Timeframe: Up to Day 30

Part 1 - Number of Participants with Clinically Significant Changes in Clinical Chemistry

Timeframe: Up to Day 15

Part 2 - Number of Participants with Clinically Significant Changes in Clinical Chemistry

Timeframe: Up to Day 30

Part 1 - Number of Participants with Clinically Significant Changes in Laboratory Values for Urinalysis

Timeframe: Up to Day 15

Part 2 - Number of Participants with Clinically Significant Changes in Urinalysis

Timeframe: Up to Day 30

Part 1 - Number of Participants with Clinically Significant Changes in Vital Signs

Timeframe: Up to Day 15

Part 2 - Number of Participants with Clinically Significant Changes in Vital Signs

Timeframe: Up to Day 30

Part 1 - Number of Participants with Clinically Significant Changes in 12 Lead Electrocardiogram Readings

Timeframe: Up to Day 15

Part 2 - Number of Participants with Clinically Significant Changes in 12 Lead Electrocardiogram Readings

Timeframe: Up to Day 30

Part 1 - Number of Participants with Clinically Significant Changes in 24 Hour Telemetry

Timeframe: Up to Day 2

Part 2 - Number of Participants with Clinically Significant Changes in 24 Hour Telemetry

Timeframe: Up to Day 15

Secondary outcomes:

Part 1 - Maximum observed plasma concentration (Cmax) of GSK3996401 following administration of GSK4347859

Timeframe: Up to Day 3

Part 1 - Time to maximum observed plasma concentration (Tmax) of GSK3996401 following administration of GSK4347859

Timeframe: Up to Day 3

Part 1 - Apparent terminal half-life (t½) of GSK3996401 following administration of GSK4347859

Timeframe: Up to Day 3

Part 1 - Area under the concentration-time curve from zero to last quantifiable concentration [AUC(0-t)] of GSK3996401 following administration of GSK4347859

Timeframe: Up to Day 3

Part 1 - Area under the concentration-time curve from time zero to infinity [AUC(0-∞)] of GSK3996401 following administration of GSK4347859

Timeframe: Up to Day 3

Part 1 - Area under the concentration-time curve over each dosing interval [AUC(0-tau)] of GSK3996401 following administration of GSK4347859

Timeframe: Up to Day 3

Part 1 - Area under the concentration-time curve from time zero to 24 hours after dosing [AUC(0-24)] of GSK3996401 following administration of GSK4347859

Timeframe: Up to Day 3

Part 1 - Observed trough concentrations (Ctrough) of GSK3996401 following administration of GSK4347859

Timeframe: Up to Day 3

Part 2 – Cmax of GSK3996401 following administration of single and repeat doses of GSK4347859

Timeframe: Up to Day 15

Part 2 – Tmax of GSK3996401 following administration of single and repeat doses of GSK4347859

Timeframe: Up to Day 15

Part 2 – Area under the concentration-time curve from time zero to 24 hours after dosing [AUC(0-24)] of GSK3996401 following administration single and repeat doses of GSK4347859

Timeframe: Up to Day 15

Part 2 - Observed trough concentrations (Ctrough) of GSK3996401 following administration of GSK4347859

Timeframe: Up to Day 15

Part 2 - Area under the concentration-time curve over each dosing interval [AUC(0-tau)] of GSK3996401 following administration of GSK4347859

Timeframe: Up to Day 15

Interventions:
  • Drug: GSK4347859
  • Drug: Placebo
    • Enrollment:
    65
    Primary completion date:
    2026-14-07
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Systemic Lupus Erythematosus
    Product
    Not applicable
    Collaborators
    Not applicable
    Study date(s)
    January 2024 to July 2026
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    18 - 55 Years
    Accepts healthy volunteers
    Yes
    • Participants who are overtly healthy.
    • Participant has a confirmed positive vaccination status for severe acute respiratory syndrome–related Coronavirus (2 SARS-CoV-2) and, if study dosing is during Flu season, influenza vaccines administered at least 30 days prior to dosing in the study.
    • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disorders. - Abnormal blood pressure
    • A clinically significant ECG abnormality at screening.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Participants who are overtly healthy.
    • Participant has a confirmed positive vaccination status for severe acute respiratory syndrome–related Coronavirus (2 SARS-CoV-2) and, if study dosing is during Flu season, influenza vaccines administered at least 30 days prior to dosing in the study.
    • Fitzpatrick skin type I, II or III (Part 2 only).
    • Body weight greater than or equal to (≥) 50 kilogram (kg) and body mass index (BMI) within the range 18 –32 kilogram per meter square (kg/m^2) (inclusive).
    • Male and female of non-childbearing potential.
    • Capable of giving signed informed consent.
    Exclusion criteria:
    • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disorders.
    • Abnormal blood pressure
    • A clinically significant ECG abnormality at screening.
    • Evidence of active or latent tuberculosis (TB).
    • Symptomatic herpes zoster within 3 months prior to screening
    • Alanine transaminase (ALT) >1 times upper limit of normal (ULN).
    • Total bilirubin >1.5x ULN [isolated total bilirubin >1.5x ULN is acceptable if total bilirubin is fractionated and direct bilirubin <35- percentage (%)].
    • History of malignancy.
    • Participants with known Corona virus disease-2019 (COVID-19) positive contacts as per local/site Guidelines
    • Prior moderate/severe COVID-19 infection requiring oxygen supplementation or admission to hospital.
    • Live vaccine(s) within 1 month prior to screening or plan to receive such vaccines during the study.
    • Past or intended use of over-the-counter or prescription medication including herbal medications within 7 days prior to dosing
    • The participant has participated in a clinical trial and has received an investigational product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product and dosing.
    • Current enrolment or past participation in this clinical study
    • Presence of Hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention
    • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
    • Positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study
    • Positive pre-study drug/alcohol screen
    • Regular use of known drugs of abuse, including tetrahydrocannabinol.
    • Positive Human immunodeficiency virus (HIV) antibody test
    • Positive smoke breathalyzer levels indicative of smoking history at screening and each in-house admission to the clinical research unit or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
    • Estimated glomerular filtration rate (eGFR) of less than (<) 90 (millilitre/minute) mL/min/1.73 m2 and / or Urine Albumin Creatinine (UACR) of >30 milligram per gram (mg/g) at screening
    • A positive confirmation of SARS-CoV-2 infection or signs and symptoms suggestive of SARS-CoV-2 at screening or pre-dose
    • The participant has a phobia to needles
    • An average weekly alcohol intake of > 14 units. For Part 2:
    • History of benign skin conditions including but not limited to photosensitivity, atopic dermatitis, chronic eczema, psoriasis, urticaria, vitiligo, post-inflammatory hyperpigmentation, or keloid or hypertrophic scaring that in the opinion of the Investigator would impact study participation.
    • History or presence of excessive bleeding or coagulation disorders.
    • History of adverse reaction to local anesthetic.
    • The presence of widespread acne, freckles, naevi, tattoos, birthmarks, piercings, scarring or other skin variations within the proposed Ultraviolet B (UVB) exposure challenge area
    • Direct UV exposure to the areas of the body to be studied within 2 weeks.
    • Unable to refrain from exposure to extended and direct sunlight or use of artificial tanning devices, self-tanning products, sun blocking products or other topical products (including moisturizers and makeup) on the areas of the body to be studied.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Cambridge, United Kingdom, CB2 2GG
    Status
    Study Stopped
    Contact us
    Location
    GSK Investigational Site
    Nottingham, United Kingdom, NG11 6JS
    Status
    Study Complete
    Contact us

    Study documents

    No study documents available.

    Results overview

    Study Results yet to be posted

    Recruitment status
    Other
    Actual primary completion date
    Not applicable
    Actual study completion date
    Not applicable

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website